Trademark: 86680061
Word
Q2 SOLUTIONS
Status
Registered
Status Code
700
Status Date
Tuesday, July 25, 2017
Serial Number
86680061
Registration Number
5251668
Registration Date
Tuesday, July 25, 2017
Mark Type
5000
Filing Date
Wednesday, July 1, 2015
Published for Opposition
Tuesday, October 4, 2016

Trademark Owner History
Q Squared Solutions Holdings LLC - Original Registrant

Classifications
41 Educational and training services, namely, conducting training programs, seminars, classes, conferences and workshops in the fields of health policy, health management, and disease management, patient management, and pharmaceutical, pharmacogenomic, biomarker, medical device and diagnostics, and distributing course materials in connection therewith; teaching and training in information technology for the healthcare industry; all of the foregoing relating to clinical trials, clinical research, medical and scientific laboratory services, biopharmaceutical, biomarker, diagnostics and medical product and device development, and research, testing, regulatory approval and commercialization of diagnostics, biopharmaceuticals, biomarkers and medical products and devices and none of the foregoing for use in the field of or related to Medicare or other governmental health programs
9 Computer software for providing, managing and analyzing laboratory clinical trial data and laboratory and clinical trials information in the fields of pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, medical, health care, health management and disease management fields; computer software that allows remote access to clinical trial laboratory data and laboratory and clinical trials information; computer software for use in collecting and reporting medical data relating to patient medical conditions for clinical trials, research, peri- and post-approval studies, quality improvement, and patient support programs; none of the foregoing for use in the field of Medicare
35 Computerized database management and data processing services in the pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics fields; providing business information, namely, information related to regulatory approval and marketing of drugs, devices, health care or medical products and services, and biologics; business research in the field of health care; business consultation in the field of healthcare; business technology consulting, namely, business consulting services relating to the integration of the areas of business process technology, change management and operational sustainability in the healthcare, medical, health management and disease management fields; none of the foregoing for use in the field of Medicare
45 Regulatory compliance research and consulting services in the fields of health care, clinical trials, development and testing of drugs, devices, biologics and methodologies used in the pharmaceutical industry, biotechnology industry and the medical device and diagnostics industry; conducting regulatory compliance audits for others in the fields of health care, clinical trials, pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, and medical device and diagnostics; consulting services in the fields of regulatory affairs, namely, regulatory compliance consulting in the field of prescription drug sampling; manufacturing compliance and validation procedures, namely, reviewing standards and practices to assure compliance with clinical trial regulations, medical and laboratory testing services; providing regulatory information, namely, providing regulatory compliance information regarding the examination and approval process of pharmaceutical, biotechnical, medical and diagnostic products and methodologies by governmental regulatory bodies; providing regulatory compliance consulting services relating to the development and validation of drugs, devices and biologics, namely, assisting others in implementing procedures that comply with regulatory requirements; none of the foregoing for use in the field of Medicare
44 Providing health and medical information; providing pharmaceutical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing medical information relating to pharmacogenomics and biomarkers; health management and disease management medical information to others; medical evaluation services; medical consulting services in the fields of health care, medicine, life sciences, and pharmaceuticals, biopharmaceuticals, biomarkers, pharmacogenomics, medical device and diagnostics; providing an online interactive computer database in the field of healthcare featuring healthcare information; providing an Internet website portal featuring medical and healthcare information in the fields of medical services, health care, health management and disease management; providing an online searchable database via the internet featuring medical and healthcare information in the fields of medical services, medical devices and diagnostics, health care, health management and disease management; none of the foregoing for use in the field of Medicare
42 Clinical research and testing services, in the fields of clinical trials, health care products, pharmaceutical products, pharmacogenomics products, biomarker products, biopharmaceutical products, medical devices and diagnostics products; product development consultation in the fields of health care, medical products and devices; health care research and product development services; medical and laboratory testing services for research purposes; laboratory testing services for research purposes in the fields of health care, clinical trials, pharmaceutical, pharmacogenomics, biomarker, biopharmaceutical, medical device and diagnostics; consultancy in the design, planning and implementation project management of clinical trials; health care medical research consultancy; product development consultancy in the fields of medical diagnostics, medical devices, pharmacology, pharmacogenomics, biomarkers and biopharmaceutical research; managing, namely, monitoring, coordinating and implementing clinical studies being clinical trials on human subjects for others for research purposes; medical and scientific research in the fields of healthcare and medical diagnostics; providing temporary use of non-downloadable, web-based software application for providing access to information and data in the clinical trials, pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields and for organizing and analyzing said data and information and preparing reports therefrom, providing temporary use of non-downloadable software for providing, managing and analyzing laboratory clinical trial data and information in the fields of pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields; providing temporary use of non-downloadable software that allows remote access to clinical trial peri- and post-approval laboratory data and information; providing temporary use of non-downloadable software for use in collecting and reporting medical data relating to patient medical conditions for research; providing scientific and medical research information relating to the development and validation of drugs, pharmaceutical products, medical products, medical devices and biologics; providing an internet website portal featuring scientific and medical research information in the fields of clinical trials, pharmaceutical research, pharmacogenomic and biomarker consultation, biopharmaceutical consultation, medical devices and diagnostics, life sciences research, and medical research; providing an online searchable database via the internet featuring medical and scientific research information in the fields of clinical trials, companion diagnostics, pharmaceutical research, pharmacogenomic and biomarkers, biopharmaceuticals, medical devices and diagnostics, life sciences research, and medical research; all of the foregoing relating to clinical trials, clinical research, medical and scientific laboratory services, biopharmaceutical, biomarker, diagnostics and medical product and device development, and research, testing, regulatory approval and commercialization of diagnostics, biopharmaceuticals, biomarkers and medical products and devices and none of the foregoing for use in the field of or related to Medicare or other governmental health programs
The mark consists of the letter "Q" followed by a superscript number "2" followed by the word "Solutions".
Q TWO SOLUTIONS
Color is not claimed as a feature of the mark.
"SOLUTIONS"

Trademark Events
Jan 25, 2024
Teas Section 8 & 15 Received
Jul 25, 2022
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Dec 18, 2018
Teas Change Of Correspondence Received
Jul 25, 2017
Registered-Principal Register
Jun 21, 2017
Notice Of Acceptance Of Statement Of Use E-Mailed
Jun 20, 2017
Allowed Principal Register - Sou Accepted
Jun 6, 2017
Statement Of Use Processing Complete
May 10, 2017
Use Amendment Filed
Jun 6, 2017
Case Assigned To Intent To Use Paralegal
May 10, 2017
Teas Statement Of Use Received
Nov 29, 2016
Noa E-Mailed - Sou Required From Applicant
Oct 4, 2016
Official Gazette Publication Confirmation E-Mailed
Oct 4, 2016
Published For Opposition
Sep 14, 2016
Notification Of Notice Of Publication E-Mailed
Aug 29, 2016
Law Office Publication Review Completed
Aug 23, 2016
Approved For Pub - Principal Register
Aug 18, 2016
Examiner's Amendment Entered
Aug 17, 2016
Assigned To Lie
Aug 17, 2016
Notification Of Examiners Amendment E-Mailed
Aug 17, 2016
Examiners Amendment E-Mailed
Aug 17, 2016
Examiners Amendment -Written
May 9, 2016
Notification Of Final Refusal Emailed
May 9, 2016
Final Refusal E-Mailed
May 9, 2016
Final Refusal Written
Apr 16, 2016
Teas/Email Correspondence Entered
Apr 15, 2016
Correspondence Received In Law Office
Apr 15, 2016
Teas Response To Office Action Received
Oct 20, 2015
Notification Of Priority Action E-Mailed
Oct 20, 2015
Priority Action E-Mailed
Oct 20, 2015
Priority Action Written
Oct 12, 2015
Assigned To Examiner
Jul 8, 2015
Notice Of Pseudo Mark E-Mailed
Jul 7, 2015
New Application Office Supplied Data Entered
Jul 4, 2015
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24